SG11201407613RA - Process for making hydroxylated cyclopentylpyrimidine compounds - Google Patents

Process for making hydroxylated cyclopentylpyrimidine compounds

Info

Publication number
SG11201407613RA
SG11201407613RA SG11201407613RA SG11201407613RA SG11201407613RA SG 11201407613R A SG11201407613R A SG 11201407613RA SG 11201407613R A SG11201407613R A SG 11201407613RA SG 11201407613R A SG11201407613R A SG 11201407613RA SG 11201407613R A SG11201407613R A SG 11201407613RA
Authority
SG
Singapore
Prior art keywords
international
boulder
colorado
array biopharma
walnut street
Prior art date
Application number
SG11201407613RA
Other languages
English (en)
Inventor
Jonathan W Lane
Travis Remarchuk
Sagar Shakya
Keith L Spencer
Peter J Stengel
Original Assignee
Array Biopharma Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc, Genentech Inc filed Critical Array Biopharma Inc
Publication of SG11201407613RA publication Critical patent/SG11201407613RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201407613RA 2012-05-17 2013-05-17 Process for making hydroxylated cyclopentylpyrimidine compounds SG11201407613RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261648421P 2012-05-17 2012-05-17
US201361785281P 2013-03-14 2013-03-14
PCT/US2013/041624 WO2013173736A1 (en) 2012-05-17 2013-05-17 Process for making hydroxylated cyclopentylpyrimidine compounds

Publications (1)

Publication Number Publication Date
SG11201407613RA true SG11201407613RA (en) 2015-01-29

Family

ID=48534507

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407613RA SG11201407613RA (en) 2012-05-17 2013-05-17 Process for making hydroxylated cyclopentylpyrimidine compounds

Country Status (19)

Country Link
US (1) US9309204B2 (xx)
EP (1) EP2861583B1 (xx)
JP (1) JP6214636B2 (xx)
KR (1) KR20150020211A (xx)
CN (1) CN104487430B (xx)
AU (1) AU2013262568B2 (xx)
BR (1) BR112014028570A2 (xx)
CA (1) CA2873653A1 (xx)
DK (1) DK2861583T3 (xx)
ES (1) ES2588878T3 (xx)
HK (1) HK1208673A1 (xx)
IL (1) IL235714A0 (xx)
MA (1) MA37649B1 (xx)
MX (1) MX2014013865A (xx)
PL (1) PL2861583T3 (xx)
RU (1) RU2014151017A (xx)
SG (1) SG11201407613RA (xx)
SI (1) SI2861583T1 (xx)
WO (1) WO2013173736A1 (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2582557T3 (es) 2012-05-17 2016-09-13 Array Biopharma, Inc. Proceso para la preparación de compuestos hidroxilados de ciclopentilpirimidina
KR20200074252A (ko) 2012-05-17 2020-06-24 제넨테크, 인크. 무정형 형태의 akt 저해성 피리미디닐 - 사이클로펜탄 화합물, 조성물 및 이들의 방법
CA2873661C (en) 2012-05-17 2020-07-21 Genentech, Inc. Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
WO2013173779A1 (en) 2012-05-17 2013-11-21 Genentech, Inc. Process for making amino acid compounds
KR102493603B1 (ko) 2013-11-15 2023-01-31 에프. 호프만-라 로슈 아게 피리미딘일사이클로펜테인 화합물의 제조 방법
AU2014356984B2 (en) * 2013-11-27 2018-01-04 Sunshine Lake Pharma Co., Ltd. Processes for preparing dihydropyrimidine derivatives and intermediates thereof
MA51165A (fr) 2014-09-26 2020-10-21 Hoffmann La Roche Procédés de préparation de composés de (cyclopentyl[d]pyrimidin-4-yl)pipérazine
MX2022015322A (es) 2020-06-16 2023-01-11 Hoffmann La Roche Proceso para elaborar compuestos de ciclopentilpirimidina hidroxilada.
KR20230035773A (ko) * 2021-09-06 2023-03-14 연세대학교 산학협력단 Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9408197A (pt) 1993-12-12 1997-08-26 Agrogene Ltd Método para proteger plantas contra doenças fúngicas
WO1998044797A1 (en) 1997-04-07 1998-10-15 Merck & Co., Inc. A method of treating cancer
US6201023B1 (en) 1997-06-10 2001-03-13 Agrogene Ltd. Methods and compositions to protect crops against plant parasitic nematodes
EP0982300A3 (en) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
JP2003524618A (ja) 1999-03-03 2003-08-19 メルク エンド カムパニー インコーポレーテッド プレニル蛋白トランスフェラーゼ阻害剤
JP4627944B2 (ja) * 1999-06-03 2011-02-09 あすか製薬株式会社 置換ピラゾール化合物
WO2001022963A1 (en) 1999-09-27 2001-04-05 Merck & Co., Inc. Method of preventing osteoporosis
CA2526506A1 (en) 2003-06-09 2004-12-16 Boehringer Ingelheim International Gmbh Inhibitors of papilloma virus
RU2006121990A (ru) 2003-11-21 2007-12-27 Эррэй Биофарма Инк. (Us) Ингибиторы протеинкиназ акт
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
UA95641C2 (xx) 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
JP5157576B2 (ja) 2007-05-14 2013-03-06 住友化学株式会社 光学活性2−アルキル−1,1,3−トリアルコキシカルボニルプロパンの製造方法
ES2533557T3 (es) 2007-07-05 2015-04-13 Array Biopharma, Inc. Pirimidil ciclopentanos como inhibidores de proteína cinasa AKT
US20100298289A1 (en) 2007-10-09 2010-11-25 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
NZ586346A (en) 2008-01-09 2012-02-24 Array Biopharma Inc Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
AU2009303475B2 (en) * 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
JP5734956B2 (ja) 2009-04-15 2015-06-17 アッヴィ・インコーポレイテッド 抗ウィルス化合物
BR112012011328A2 (pt) * 2009-10-23 2016-11-22 Lilly Co Eli inibidores de akt
PT2592933T (pt) 2010-07-16 2017-05-23 Gaweco Anderson Inibidores de mif e suas utilizações
WO2012177925A1 (en) 2011-06-21 2012-12-27 The Board Institute, Inc. Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
CA2873661C (en) 2012-05-17 2020-07-21 Genentech, Inc. Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
ES2582557T3 (es) 2012-05-17 2016-09-13 Array Biopharma, Inc. Proceso para la preparación de compuestos hidroxilados de ciclopentilpirimidina
WO2013173779A1 (en) 2012-05-17 2013-11-21 Genentech, Inc. Process for making amino acid compounds
US20140121193A1 (en) 2012-11-01 2014-05-01 Robert S. Katz Methods for treating fibromyalgia
US20150376198A1 (en) 2013-02-18 2015-12-31 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
CN105473141A (zh) 2013-03-15 2016-04-06 实发生物医学公司 治疗和/或预防心血管疾病的抗pcsk9化合物和方法

Also Published As

Publication number Publication date
AU2013262568A1 (en) 2015-01-22
EP2861583B1 (en) 2016-06-29
IL235714A0 (en) 2015-02-01
HK1208673A1 (en) 2016-03-11
PL2861583T3 (pl) 2016-12-30
US20150099881A1 (en) 2015-04-09
AU2013262568B2 (en) 2017-08-31
MA37649A1 (fr) 2016-06-30
EP2861583A1 (en) 2015-04-22
RU2014151017A (ru) 2016-07-10
JP2015518837A (ja) 2015-07-06
US9309204B2 (en) 2016-04-12
KR20150020211A (ko) 2015-02-25
ES2588878T3 (es) 2016-11-07
MA37649B1 (fr) 2017-03-31
WO2013173736A1 (en) 2013-11-21
SI2861583T1 (sl) 2016-10-28
BR112014028570A2 (pt) 2018-04-24
JP6214636B2 (ja) 2017-10-18
MX2014013865A (es) 2015-05-07
CA2873653A1 (en) 2013-11-21
CN104487430B (zh) 2016-08-24
CN104487430A (zh) 2015-04-01
DK2861583T3 (en) 2016-10-03

Similar Documents

Publication Publication Date Title
SG11201407613RA (en) Process for making hydroxylated cyclopentylpyrimidine compounds
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201804152RA (en) Heterocyclic compounds as immunomodulators
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201807834WA (en) Bridged bicyclic inhibitors of menin-mll and methods of use
SG11201909278SA (en) Fungicidal oxadiazoles
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201407591PA (en) Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
SG11201804098TA (en) Purinones as ubiquitin-specific protease 1 inhibitors
SG11201811414TA (en) Heterocyclic compounds as immunomodulators
SG11201808990QA (en) Compositions for topical application of compounds
SG11201808878UA (en) Heterocyclic compounds as ret kinase inhibitors
SG11201907544VA (en) Jak inhibitors containing a 4-membered heterocyclic amide
SG11201408067YA (en) Crystalline forms of a bruton's tyrosine kinase inhibitor
SG11201804934PA (en) Novel Compounds
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201500005SA (en) Pyrimidine pyrazolyl derivatives
SG11201408186TA (en) Pyridinone and pyridazinone derivatives
SG11201408271VA (en) Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases
SG11201407793TA (en) Compounds and compositions for modulating egfr activity
SG11201403402VA (en) Compounds
SG11201408821SA (en) Selective pi3k delta inhibitors
SG11201407546QA (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
SG11201406903SA (en) Cell culture compositions and methods for polypeptide production